recombinant human insulin
- Generic Name
- recombinant human insulin
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Diabetes Mellitus Type 1
- Interventions
- First Posted Date
- 2011-04-13
- Last Posted Date
- 2013-07-26
- Lead Sponsor
- Biodel
- Target Recruit Count
- 13
- Registration Number
- NCT01334151
- Locations
- 🇺🇸
Profil Institute for Clinical Research, Inc. (PICR), Chula Vista, California, United States
Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock
Phase 3
Completed
- Conditions
- Septic Shock
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2010-04-06
- Lead Sponsor
- University of Versailles
- Target Recruit Count
- 508
- Registration Number
- NCT00320099
- Locations
- 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷Hôpital central, Nancy, France
🇫🇷Hôpital Avicenne, Bobigny, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath